Hematological Neoplasms

The editor has selected an “Oral Presentation” (S240)[2] to provide insights into the efficacy and toxicity of anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed or refractory primary mediastinal B-cell lymphoma (R/R PMBL), and to investigate factors associated with treatment outcomes.

June 22nd is designated as CAR-T Day, to commemorate the official approval and launch of Axicabtagene Ciloleucel in China, marking the beginning of the CAR-T cell therapy era in China.

The National Cancer Institute (NCI) in the United States first reported successful cases of second-generation CD19 CAR-T cell therapy.

Recently, the Department of Hematology at the University Hospital of Rennes in France published a journal review titled “Remission After CAR-T Cell Therapy: Can Lymphoma Patients Return to a Normal Life?” in the medical journal HemaSphere.

Although immunochemotherapy is initially effective, its efficacy gradually diminishes, and toxicity may accumulate.

Recently, The Lancet Haematology published the results of a phase 1 clinical trial indicating that CD30-targeted CAR-T cell therapy (ATLCAR.CD30) has the potential to serve as a consolidation treatment for high-risk Hodgkin lymphoma patients after autologous HSCT.

On May 15, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for an immunotherapy treatment for follicular lymphoma.

Primary central nervous system lymphoma (PCNSL) is a central nervous system-confined non-Hodgkin lymphoma (NHL), with the pathological diagnosis being mainly diffuse large B-cell lymphoma.

On May 30, 2024, Bristol Myers Squibb announced that the U.S. FDA has approved the expanded indication of its CAR-T therapy Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including those who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.

In January 2022, Bristol Myers Squibb (BMS) announced the pre-specified interim analysis data from the pivotal Phase 3 TRANSFORM study (NCT03575351).

On Thursday, May 31, 2024, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), making this CD19-targeted cellular therapy the broadest approved for B-cell malignancies.